- Home
- AYTU vs IMRN Comparison
AYTU vs IMRN Comparison
Compare AYTU & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AYTU
- IMRN
- Stock Information
- Founded
- AYTU N/A
- IMRN 1994
- Country
- AYTU United States
- IMRN Australia
- Employees
- AYTU N/A
- IMRN N/A
- Industry
- AYTU Biotechnology: Pharmaceutical Preparations
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- AYTU Health Care
- IMRN Health Care
- Exchange
- AYTU Nasdaq
- IMRN Nasdaq
- Market Cap
- AYTU 9.6M
- IMRN 9.2M
- IPO Year
- AYTU N/A
- IMRN N/A
- Fundamental
- Price
- AYTU $2.20
- IMRN $1.75
- Analyst Decision
- AYTU Strong Buy
- IMRN Strong Buy
- Analyst Count
- AYTU 2
- IMRN 1
- Target Price
- AYTU $10.00
- IMRN $5.00
- AVG Volume (30 Days)
- AYTU 207.1K
- IMRN 23.5K
- Earning Date
- AYTU 05-14-2025
- IMRN 09-08-2025
- Dividend Yield
- AYTU N/A
- IMRN N/A
- EPS Growth
- AYTU N/A
- IMRN N/A
- EPS
- AYTU N/A
- IMRN N/A
- Revenue
- AYTU $81,659,000.00
- IMRN $4,048,286.00
- Revenue This Year
- AYTU N/A
- IMRN N/A
- Revenue Next Year
- AYTU $8.68
- IMRN N/A
- P/E Ratio
- AYTU N/A
- IMRN N/A
- Revenue Growth
- AYTU 0.41
- IMRN 82.90
- 52 Week Low
- AYTU $0.95
- IMRN $1.50
- 52 Week High
- AYTU $2.88
- IMRN $2.87
- Technical
- Relative Strength Index (RSI)
- AYTU 62.85
- IMRN 49.16
- Support Level
- AYTU $2.04
- IMRN $1.67
- Resistance Level
- AYTU $2.45
- IMRN $1.78
- Average True Range (ATR)
- AYTU 0.13
- IMRN 0.10
- MACD
- AYTU 0.01
- IMRN -0.00
- Stochastic Oscillator
- AYTU 68.00
- IMRN 51.25
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.